Genmab A/S (NASDAQ:GMAB) Upgraded to Strong-Buy at Zacks Research

Genmab A/S (NASDAQ:GMAB) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Several other brokerages have also recently issued reports on GMAB. HC Wainwright upped their price target on shares of Genmab A/S from $36.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research note on Saturday, September 27th. Wall Street Zen raised shares of Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Tuesday, September 23rd. Finally, Truist Financial upped their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.80.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $33.56 on Thursday. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $33.61. The firm has a 50 day moving average price of $25.84 and a two-hundred day moving average price of $22.43. The stock has a market cap of $21.53 billion, a P/E ratio of 16.86, a price-to-earnings-growth ratio of 1.82 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Orbis Allan Gray Ltd raised its holdings in Genmab A/S by 102.8% during the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock worth $111,816,000 after buying an additional 2,895,179 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after buying an additional 2,084,966 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Genmab A/S by 112.4% during the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after buying an additional 665,893 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Genmab A/S by 111.5% during the first quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company’s stock worth $21,149,000 after buying an additional 569,345 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new position in Genmab A/S during the second quarter worth $9,236,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.